Clinical Trials

In Vivo CAR Cell Therapy: Revolutionizing Immunotherapy
Research & Development In Vivo CAR Cell Therapy: Revolutionizing Immunotherapy

Imagine a world where life-saving cancer treatments no longer require weeks of waiting for cell processing or come with a price tag in the hundreds of thousands of dollars, but instead can be administered in days at a fraction of the cost. This is the promise of in vivo CAR cell therapy, an

Can Hyrnuo Redefine Treatment for Rare Lung Cancer?
Research & Development Can Hyrnuo Redefine Treatment for Rare Lung Cancer?

In a landscape where lung cancer remains one of the most challenging diseases to treat, particularly for rare subsets of patients, a new development has sparked hope among clinicians and affected individuals alike. Bayer’s recently approved drug, sevabertinib, marketed as Hyrnuo, has gained

Why Are Outpatient Clinics Vital for Drug Trials?
Research & Development Why Are Outpatient Clinics Vital for Drug Trials?

In the intricate world of drug development, where every trial holds the potential to transform lives, a quiet revolution is unfolding in the unassuming spaces of suburban medical corridors, reshaping how research reaches communities. Outpatient clinics, traditionally viewed as mere venues for

Can Pyrukynd Redefine Sickle Cell Treatment Despite Setbacks?
Research & Development Can Pyrukynd Redefine Sickle Cell Treatment Despite Setbacks?

I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with a wealth of experience in research and development, as well as a keen understanding of technological innovation in the industry. Today, we’re diving into the recent developments surrounding Agios Pharmaceuticals and their

Lifordi Secures $112M for Targeted RA Therapy LFD-200
Research & Development Lifordi Secures $112M for Targeted RA Therapy LFD-200

In a groundbreaking development for rheumatoid arthritis treatment, Lifordi Immunotherapeutics, a clinical-stage biotech firm headquartered in Burlington, Massachusetts, has successfully raised $112 million in a funding round led by Sanofi Ventures, with continued support from prominent investors

What Does High-Dose Nusinersen Mean for SMA Treatment?
Research & Development What Does High-Dose Nusinersen Mean for SMA Treatment?

Spinal Muscular Atrophy (SMA), a rare genetic disorder that causes progressive muscle weakness and significant life challenges, has long been a focus of medical research seeking transformative solutions for affected individuals across all ages. A pivotal moment in this journey arrived on November

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later